Despite significant advances in their molecular pathogenesis, skeletal vascular tumors remain diagnostically challenging due to their aggressive radiologic appearance and significant morphologic overlap. Within the epithelioid category and at the benign end of the spectrum, recurrent FOS/FOSB fusions have defined most epithelioid hemangiomas, distinguishing them from epithelioid hemangioendothelioma and angiosarcoma. More recently, the presence of EWSR1/FUS :: NFATC1/2 fusions emerged as the genetic hallmark of a novel group of unusual vascular proliferations, often displaying epithelioid morphology, with alternating vasoformative and solid growth, variable atypia, reminiscent of composite hemangioendothelioma. In this study, we further our understanding and morphologic spectrum of NFATC -fusion positive vascular neoplasms by describing 9 new cases, including soft tissue locations and novel fusion partners. Combining with the initial cohort of 5 cases, a total of 14 patients were analyzed, showing slight female predilection and an age range of 10 to 66 (mean 42 y). Twelve patients had solitary lesions, while 2 had multifocal polyostotic (pelvic bones) disease. Overall, 12 lesions were intra-osseous and 2 in soft tissue. By targeted RNA Fusion panels or FISH, there were 6 cases of EWSR1::NFATC1 , 4 EWSR1::NFATC2 , 2 FUS::NFATC2 , 1 EWSR1 rearrangement, and 1 with a novel FABP4::NFATC2 fusion. Follow-up was available in 4 patients. One patient experienced 2 local recurrences, 11 and 15 years postdiagnosis, and one patient experienced progressive disease despite multimodality treatment (curettings, embolization, radiation) over 3 years. In summary, our extended investigation confirms that NFATC -related fusions define a distinct group of vascular neoplasms with variable architecture, epithelioid phenotype, and cytologic atypia, commonly located in the bone, occasionally multifocal and with potential for local recurrence and aggressive behavior but no metastatic potential. Molecular analysis is recommended in diagnostically challenging cases with atypical histology to exclude malignancy.

Biopticka Laboratory Pilsen Czech Republic

Bordeaux Institute of Oncology BRIC INSERM Bordeaux University Bergonié Institute Bordeaux France

Cedars Sinai Medical Center Los Angeles CA

Department of Biopathology Institut Bergonié Comprehensive Cancer Center

Department of Pathology and Lab Medicine Memorial Sloan Kettering Cancer Center New York NY

Department of Pathology and Laboratory Medicine Dartmouth Health

Department of Pathology Charles University Faculty of Medicine in Plzen Czech Republic

Geisel School of Medicine at Dartmouth Lebanon NH

Robert J Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland OH

University of Pittsburgh Medical Center Shadyside Pittsburgh PA

Zobrazit více v PubMed

Evans HL, Raymond AK, Ayala AG. Vascular tumors of bone: a study of 17 cases other than ordinary hemangioma, with an evaluation of the relationship of hemangioendothelioma of bone to epithelioid hemangioma, epithelioid hemangioendothelioma, and high-grade angiosarcoma. Hum Pathol. 2003;34:680–689.

Nielsen GP, Srivastava A, Kattapuram S, et al. Epithelioid hemangioma of bone revisited: a study of 50 cases. Am J Surg Pathol. 2009;33:270–277.

Errani C, Zhang L, Panicek DM, et al. Epithelioid hemangioma of bone and soft tissue: a reappraisal of a controversial entity. Clin Orthop Relat Res®. 2012;470:1498–1506.

O’Connell JX, Kattapuram SV, Mankin HJ, et al. Epithelioid hemangioma of bone. A tumor often mistaken for low-grade angiosarcoma or malignant hemangioendothelioma. Am J Surg Pathol. 1993;17:610–617.

Huang S-C, Zhang L, Sung Y-S, et al. Frequent FOS gene rearrangements in epithelioid hemangioma: a molecular study of 58 cases with morphologic reappraisal. Am J Surg Pathol. 2015;39:1313.

Antonescu CR, Chen HW, Zhang L, et al. ZFP36‐FOSB fusion defines a subset of epithelioid hemangioma with atypical features. Genes Chromosomes Cancer. 2014;53:951–959.

van IJzendoorn DG, de Jong D, Romagosa C, et al. Fusion events lead to truncation of FOS in epithelioid hemangioma of bone. Genes Chromosomes Cancer. 2015;54:565–574.

Tsuda Y, Suurmeijer AJ, Sung YS, et al. Epithelioid hemangioma of bone harboring FOS and FOSB gene rearrangements: a clinicopathologic and molecular study. Genes Chromosomes Cancer. 2021;60:17–25.

Antonescu CR, Huang S-C, Sung Y-S, et al. Novel GATA6-FOXO1 fusions in a subset of epithelioid hemangioma. Mod Pathol. 2021;34:934–941.

Errani C, Zhang L, Sung YS, et al. A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50:644–653.

Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52:775–784.

Dermawan JK, Azzato EM, Billings SD, et al. YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases. Mod Pathol. 2021;34:2211–2221.

Tanas MR, Sboner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011;3:98ra82-.

Dashti NK, Dickson BC, Zhang L, et al. A unique epithelioid vascular neoplasm of bone characterized by EWSR1/FUS‐NFATC1/2 fusions. Genes Chromosomes Cancer. 2021;60:762–771.

Ong SL, Lam SW, van den Akker BE, et al. Expanding the spectrum of EWSR1-NFATC2-rearranged benign tumors: a common genomic abnormality in vascular malformation/hemangioma and simple bone cyst. Am J Surg Pathol. 2021;45:1669.

Chung CT, Antonescu CR, Dickson BC, et al. Pediatric fibromyxoid soft tissue tumor with PLAG1 fusion: a novel entity? Genes Chromosomes Cancer. 2021;60:263–271.

Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20:1479–1484.

Antonescu CR, Zhang L, Chang NE, et al. EWSR1‐POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty‐six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer. 2010;49:1114–1124.

Tsuda Y, Zhang L, Meyers P, et al. The clinical heterogeneity of round cell sarcomas with EWSR1/FUS gene fusions: impact of gene fusion type on clinical features and outcome. Genes Chromosomes Cancer. 2020;59:525–534.

Szuhai Kr, IJszenga M, de Jong D, et al. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res. 2009;15:2259–2268.

Diaz-Perez JA, Nielsen GP, Antonescu C, et al. EWSR1/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review. Hum Pathol. 2019;90:45–53.

Bode-Lesniewska B, Fritz C, Exner GU, et al. EWSR1-NFATC2 and FUS-NFATC2 gene fusion-associated mesenchymal tumors: clinicopathologic correlation and literature review. Sarcoma. 2019;26:9386390.

Perry KD, Al-Lbraheemi A, Rubin BP, et al. Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant. Mod Pathol. 2017;30:1589–1602.

Antonescu CR, Dickson BC, Sung Y-S, et al. Recurrent YAP1 and MAML2 gene rearrangements in retiform and composite hemangioendothelioma. Am J Surg Pathol. 2020;44:1677–1684.

Arbajian E, Magnusson L, Brosjö O, et al. A benign vascular tumor with a new fusion gene: EWSR1-NFATC1: in hemangioma of the bone. Am J Surg Pathol. 2013;37:613–616.

WHO Classification of Tumours: soft Tissue and Bone Tumours . 5th ed. International Agency for Research on Cancer; 2020.

Rosenbaum E, Jadeja B, Xu B, et al. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod Pathol. 2020;33:591–602.

Wang GY, Thomas DG, Davis JL, et al. EWSR1-NFATC2 translocation-associated sarcoma clinicopathologic findings in a rare aggressive primary bone or soft tissue tumor. Am J Surg Pathol. 2019;43:1112–1122.

Watson S, Perrin V, Guillemot D, et al. Transcriptomic definition of molecular subgroups of small round cell sarcomas. Journal Pathol. 2018;245:29–40.

Perret R, Escuriol J, Velasco V, et al. NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker. Mod Pathol. 2020;33:1930–1944.

Szuhai K, IJszenga M, Tanke HJ, et al. Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma. Cancer Genet Cytogenet. 2007;172:12–22.

Pižem J, Šekoranja D, Zupan A, et al. FUS-NFATC2 or EWSR1-NFATC2 fusions are present in a large proportion of simple bone cysts. Am J Surg Pathol. 2020;44:1623–1634.

Hung YP, Fisch AS, Diaz‐Perez JA, et al. Identification of EWSR1–NFATC2 fusion in simple bone cysts. Histopathology. 2021;78:849–856.

Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136–142.

Rao A. NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. Immunol Today. 1994;15:274–281.

Serfling E, Avots A, Neumann M. The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Biochim Biophys Acta (BBA). 1995;1263:181–200.

Northrop JP, Ho SN, Chen L, et al. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature. 1994;369:497–502.

Shaw K, Ho AM, Raghavan A, et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci. 1995;92:11205–11209.

Hernández GL, Volpert OV, Íñiguez MA, et al. Selective inhibition of vascular endothelial growth factor–mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med. 2001;193:607–620.

Armesilla AL, Lorenzo E, del Arco PG, et al. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol Cell Biol. 1999;19:2032–2043.

Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med. 2008;14:1236–1246.

Zaichuk TA, Shroff EH, Emmanuel R, et al. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med. 2004;199:1513–1522.

Friday BB, Pavlath GK. A calcineurin-and NFAT-dependent pathway regulates Myf5 gene expression in skeletal muscle reserve cells. J Cell Sci. 2001;114:303–310.

Horsley V, Friday BB, Matteson S, et al. Regulation of the growth of multinucleated muscle cells by an NFATC2-dependent pathway. J Cell Biol. 2001;153:329–338.

Wang J, Gardner BM, Lu Q, et al. Transcription factor Nfat1 deficiency causes osteoarthritis through dysfunction of adult articular chondrocytes. J Pathol. 2009;219:163–172.

Kim JH, Kim N. Regulation of NFATc1 in osteoclast differentiation. J Bone Metab. 2014;21:233–241.

Ho I-C, Kim JH-J, Rooney JW, et al. A potential role for the nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis. Proc Natl Acad Sci. 1998;95:15537–15541.

Perotti V, Baldassari P, Molla A, et al. NFATc2 is an intrinsic regulator of melanoma dedifferentiation. Oncogene. 2016;35:2862–2872.

Jauliac S, López-Rodriguez C, Shaw LM, et al. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol. 2002;4:540–544.

Hertzel AV, Bernlohr DA. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab. 2000;11:175–180.

Fagerberg L, Hallström BM, Oksvold P, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014;13:397–406.

Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 1996;274:1377–1379.

Zhao W, Rasheed A, Tikkanen E, et al. Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nat Genet. 2017;49:1450–1457.

Prentice KJ, Saksi J, Robertson LT, et al. A hormone complex of FABP4 and nucleoside kinases regulates islet function. Nature. 2021;600:720–726.